Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Semaglutide GLP-1: With dual benefits in managing type 2 diabetes and obesity, Semaglutide has been shown to result in an average weight loss of 14.9%
:max_bytes(150000):strip_icc()/Health-GettyImages-2153927815-0bf99cd73e2c46908d7fc0973739f6d0.jpg)
These findings imply no need to de-intensify therapy for an individual with an A1C between 6% and 7% and a low hypoglycemia risk with a long life expectancy
In a study, people taking Wegovy 7.2 mg lost about 18% of their body weight over 72 weeks, and roughly one in three lost 25% or more
SURMOUNT-1: Tirzepatide for Obesity The SURMOUNT-1 trial (NEJM, 2022) studied tirzepatide weight loss in 2,539 adults with obesity (without diabetes) over 72 weeks: STEP 1: Semaglutide for Obesity The STEP 1 trial (NEJM, 2021) studied semaglutide 2.4mg in 1,961 adults with obesity (without diabetes) over 68 weeks: Cross-Trial Summary Comparing across trials (with the caveat that indirect comparison has limitations): tirzepatide 15mg produced about 6 percentage points more weight loss than semaglutide 2.4mg over similar timeframes
These maintenance sessions are typically spaced out based on how well the results are holding up
P., Thompson, T
US$ 29.57
US$ 26.23
US$ 25.41
US$ 28.89
US$ 21.96
US$ 23.58
